Cargando...

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer

Antiestrogen therapies targeting estrogen receptor α (ER) signaling are a mainstay for patients with ER+ breast cancer. While many cancers exhibit resistance to antiestrogen therapies, a large body of clinical and experimental evidence indicates that hyperactivation of the phosphatidylinositol 3-kin...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Fox, Emily M., Arteaga, Carlos L., Miller, Todd W.
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2012
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3472546/
https://ncbi.nlm.nih.gov/pubmed/23087906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2012.00145
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!